CVALF (Covalon Technologies) Current Deferred Revenue: $0.08 Mil (As of Mar. 2026)


CVALF Covalon Technologies Ltd CVALF
83 GF Score
Price $1.51
GF Value $1.53
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Covalon Technologies Current Deferred Revenue?

Covalon Technologies CVALF -1.79% 83 Current Deferred Revenue is $0.08 Mil as of Mar. 2026. GuruFocus rates CVALF with a GF Score™ of 83/100 and a GF Value™ of $1.53 (Fairly Valued). The stock has 2 warning signs investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Covalon Technologies's current deferred revenue for the quarter that ended in Mar. 2026 was $0.08 Mil.

Covalon Technologies Current Deferred Revenue Related Terms

Covalon Technologies Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Covalon Technologies's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Covalon Technologies Current Deferred Revenue Chart

Covalon Technologies Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Current Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.33 0.16 0.06 0.05 0.00

Covalon Technologies Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.04 0.06 0.00 0.39 0.08
CVALF
83GF Score
Covalon Technologies Ltd CVALF
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of $0.08 Mil mean?
Covalon Technologies (CVALF) has a Current Deferred Revenue of $0.08 Mil as of Mar. 2026. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Covalon Technologies and its competitors.
Is Covalon Technologies' Current Deferred Revenue too high?
Covalon Technologies' current Current Deferred Revenue is $0.08 Mil. Overall, Covalon Technologies has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Covalon Technologies' Current Deferred Revenue compare to ISRG and BDX?
Covalon Technologies' Current Deferred Revenue of $0.08 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Medical Devices & Instruments company?
A good Current Deferred Revenue depends on the Medical Devices & Instruments industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Covalon Technologies and its competitors. Covalon Technologies's current Current Deferred Revenue is $0.08 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Covalon Technologies stock overvalued right now?
Based on GuruFocus' analysis, Covalon Technologies (CVALF) is currently considered Fairly Valued. The stock's GF Value™ is $1.53, compared to a current price of $1.51 — trading 1.3% below its estimated fair value. The current Current Deferred Revenue is $0.08 Mil. Covalon Technologies' overall GF Score™ is 83/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For Covalon Technologies (CVALF), the current Current Deferred Revenue is $0.08 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Covalon Technologies (CVALF) Overvalued in 2026?

Based on GuruFocus' analysis, Covalon Technologies stock appears to be undervalued. The current stock price of $1.51 is trading 1.3% below its estimated GF Value™ of $1.53. GuruFocus considers Covalon Technologies to be Fairly Valued.

Key valuation signals for CVALF:

  • Current Deferred Revenue: $0.08 Mil
  • GF Value™: $1.53 vs. price of $1.51 (1.3% below fair value)
  • GF Score™: 83/100 with 2 warning signs

No single metric tells the full story. See the CVALF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Covalon Technologies Business Description

Other Exchanges COV:Canada
Address 1660 Tech Avenue, Unit 5, Mississauga, ON, CAN, L4W 5S7
Covalon Technologies Ltd is engaged in the business of researching, developing, manufacturing, and marketing patent-protected medical products that improve patient outcomes in the areas of infection management, wound care, and surgical procedures. The company generates revenue through development contracts, licensing agreements, distribution contracts, and sales. Its products include IV dressings, surgical site protection products, vascular access protection products, and others, and its solutions include primary dressing cover, vascular access technologies, advanced wound care, sensitive skin solutions, custom medical coatings, and patient resource support.
83GF Score

Get the complete analysis for CVALF

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.51
Price
$1.53
GF Value